Effect of fenfluramine-derivative diet pills on cardiac valves: A meta-analysis of observational studies

American Heart Journal

Volumn 144, Issue 6, 2002, Pages 1065-1073

  Sachdev, Molly ^a   Miller, William C ^b   Ryan, Thomas ^a   Jollis, James G ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; FENFLURAMINE;

ARTICLE; CLINICAL TRIAL; DATA BASE; DIET RESTRICTION; DRUG EFFECT; DRUG SAFETY; HEART VALVE REGURGITATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OBESITY; PREVALENCE; PRIORITY JOURNAL; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

EID: 0036911037     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.126733     Document Type: Article

References (22)

1. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA 1999;282:1530-8.
2. Langreth R. Critics claim diet clinics misuse obesity drugs. Wall Street Journal. March 31, 1997:B8.
3. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
4. Reference deleted.
5. Burger A, Sherman H, Charlamb M, et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999;34:1153-8.
6. Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703-9.
7. Hensrud D, Connolly H, Grogan, M, et al. Echocardiographic improvement of use of fenfluramine and phentermine. Mayo Clin Proc 1999;74:1191-7.
8. Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719-24.
9. Jollis JG, Landolfo CL, Kisslo JA, et al. Fenfluramine and phentermine and cardiovascular findings: The effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101:2071-7.
10. Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713-8.
11. Lopez-Jimenez F, Aldrich H, Kumar V, et al. Fen-Phen use is not associated with an increased prevalence of significant valvular heart disease [abstract]. Circulation 1998;98:1-645.
12. Rosen M, Takeuchi M, Teupe C, et al. Are dexfenfluramine, fenfluramine, and phentermine associated with valvular heart disease? Blinded analysis of 107 patients with matched controls [abstract]. J Am Soc Echocardiogr 1998;11:510.
13. Shively B, Roldan C, Edward G, et al. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999;100:2161-7.
14. Weissman NJ, Tighe JF, Gottdiener JS, et al. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998;339:725-32.
15. Weissman NJ, Tighe JF, Gottdiener JS, et al. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. J Am Coll Cardiol 1999;34:2088-95.
16. Bowen R, Glicklich A, Khan M, et al. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
17. Bonow RO, Carabello B, de Leon AC Jr, et al. Guidelines for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998;98:1949-84 and J Heart Valve Dis 1998;7:672-707.
18. Bonow RO, Carabello B, de Leon AC Jr, et al. Guidelines for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998;98:1949-84 and J Heart Valve Dis 1998;7:672-707.
19. Mast ST, Jollis JG, Ryan T, et al. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134:261-6.
20. Schiller NB. Fen/Phen and valvular heart disease: If it sounds too bad to be true, perhaps it isn't. J Am Coll Cardiol 1999;34:1159-62.
21. Roldan CA, Decker PJ, Gelgand EA, et al. Transesophageal echo-cardiography in phen-fen users suggests frequent misdiagnosis of valvular heart disease by TTE [abstract]. J Am Coll Cardiol 1999;33:549A
22. Grayburn P, Brickner E, Rutherford J. The clinical dilemma of anorectic drug use and valvular heart disease. Am J Cardiol 1999;84:324-6.